Skip to content

Study · Animal study (in vivo) · mus musculus · 2005

2 results

Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.

Miao D, He B, Jiang Y, Kobayashi T, Sorocéanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC

The Journal of clinical investigation1 Sept 2005Cited by 187 (Europe PMC)

PMID16138191 (opens in a new tab)PMCIDPMC1193882 (opens in a new tab)DOI10.1172/jci24918 (opens in a new tab)PepBankPUB-16138191
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Pthrp+/- mice, daily PTH 1‑34 administration profoundly improved all reported skeletal microarchitecture parameters.

    In plain wordsIn mice with reduced Pthrp, daily PTH improved the measured features of bone structure.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSkeletal microarchitecture in Pthrp+/- mice
    Study

    Mus musculusn: not reported in source

    Pthrp+/- mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Daily administration of the 1-34 amino-terminal fragment of parathyroid hormone (PTH 1-34) to Pthrp+/- mice resulted in profound improvement in all parameters of skeletal microarchitecture, surpassing the improvement observed in treated WT littermates.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 02AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In Pthrp+/- mice, daily PTH 1‑34 improved skeletal microarchitecture more than in treated wild-type littermates.

    In plain wordsIn mice with reduced Pthrp, daily PTH improved bone structure more than in treated wild-type mice.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSkeletal microarchitecture
    Study

    Mus musculusn: not reported in source

    Pthrp+/- mice and wild-type littermates
    Comparator
    Treated wild-type littermates
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Daily administration of the 1-34 amino-terminal fragment of parathyroid hormone (PTH 1-34) to Pthrp+/- mice resulted in profound improvement in all parameters of skeletal microarchitecture, surpassing the improvement observed in treated WT littermates.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.